Related Experiment Video
Updated: Jul 12, 2025
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
15.7K
A plasma miRNA-based classifier for small cell lung cancer diagnosis
Michela Saviana1,2, Giulia Romano1, Joseph McElroy3
1Department of Internal Medicine, Division of Pulmonary Diseases and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Frontiers in Oncology
|October 23, 2023
Summary
This study identifies specific circulating microRNAs (miRNAs) that can help diagnose small cell lung cancer (SCLC). A classifier combining these miRNAs with clinical data improves SCLC diagnosis and surveillance.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Small cell lung cancer (SCLC) presents diagnostic challenges and a poor prognosis, with screening efforts often neglecting it in favor of non-small cell lung cancer (NSCLC).
- Circulating microRNAs (miRNAs) show aberrant expression in tumors and offer potential insights into cancer development and progression.
- Effective diagnostic and surveillance tools for SCLC are critically needed.
Purpose of the Study:
- To comprehensively assess circulating miRNAs in SCLC patients.
- To develop a miRNA-based classifier to aid in SCLC diagnosis.
- To integrate miRNA expression with clinical data for improved diagnostic accuracy.
Main Methods:
- Profiling of deregulated circulating cell-free miRNAs in plasma from SCLC patients.
- Development of a classifier using selected miRNAs and patient clinical data on a training cohort.
- Validation of the developed classifier on an independent dataset.
Main Results:
- miR-375-3p demonstrated ability to differentiate SCLC from NSCLC and Squamous Cell Carcinoma.
- A panel including miR-375-3p, miR-320b, and miR-144-3p, combined with age and race, distinguished metastatic SCLC from controls.
- The findings highlight specific miRNAs as potential biomarkers for SCLC detection.
Conclusions:
- A novel miRNA-based biomarker classifier for SCLC diagnosis is proposed.
- The classifier integrates miRNA expression with clinical demographics for improved diagnostic utility.
- This approach offers a promising strategy for SCLC diagnosis and surveillance.
